Navigation Links
Nektar in Medical News

Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results

...Scaife has previously served as Senior Vice President of Global Safety, Regulatory Affairs and Quality for Chiron Biopharma, and in similar roles with nektar Therapeutics, Elan Pharmaceuticals and Novartis Biopharma. Jay Hagan as Senior Vice President of Corporate Development and Strategy. Jay has ...

West Announces Second Quarter 2009 Results

...d $6.6 million of pre-tax income under a contract settlement agreement with nektar Therapeutics. That agreement provided for the reimbursement of the Company'...ncome): Under a February 2008 agreement reached with our former customer, nektar Therapeutics, we received full reimbursement for, among other things, sever...

Nektar Announces UCB's Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis

... nektar Advanced Polymer Conjugate Technology Used in Cimz...RANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- nektar Therapeutics (Nasdaq: NKTR ) confirmed today UCB...ge. Under the terms of the agreement between nektar and UCB,...

Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston

...N CARLOS, Calif., May 12 /PRNewswire-FirstCall/ -- nektar Therapeutics (Nasdaq: NKTR ) is scheduled to pre...Investor Relations, Events Calendar section of the nektar website: http://www.nektar.com . This Webcas...ilable for replay until June 10, 2009. About nektar ...

West Announces First Quarter 2009 Results

... included $1.3 million of pre-tax income from the settlement agreement with nektar Therapeutics, which provided for the reimbursement of the Company's costs o...ncome): Under a February 2008 agreement reached with our former customer, nektar Therapeutics, we received full reimbursement for, among other things, sever...

Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets

...CARLOS, Calif., April 29 /PRNewswire-FirstCall/ -- nektar Therapeutics (Nasdaq: NKTR ) will announce its f...he home page and Investor Relations section of the nektar website: http://www.nektar.com . The web broa...de available on the Investor Relations page at the nektar website as soon as practical after the conclusion ...

NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR

...CARLOS, Calif., April 22 /PRNewswire-FirstCall/ -- nektar Therapeutics (Nasdaq: NKTR ) presented data toda... tumo r docetaxel exposure." About nektar nektar Therapeutics is a biopharmaceutical company develo...

Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors

... CARLOS, Calif., Feb. 17 /PRNewswire-FirstCall/ -- nektar Therapeutics (Nasdaq: NKTR ) announced today tha...ur team at START is extremely pleased to work with nektar on the first clinical trial of NKTR-105 in cancer ...are in excess of $2 billion. In October 2008, nektar Therapeutics presented positive preclinical data f...

Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results

...ths ended September 30, 2008. "The turnaround at nektar is now largely complete," said Nektar President an...ed insulin collaboration by Pfizer in late 2007. nektar has continued to make significant improvements to ... approximately $66.0 million of new investments in nektar preclinical and clinical development programs. ...

West Announces Third Quarter 2008 Results

...of restructuring costs, a contract settlement with nektar Therapeutics, and discrete tax benefits recognized.... A first-quarter 2008 settlement agreement with nektar Therapeutics provided for the reimbursement of the...ments and a final settlement payment made to us by nektar net of costs incurred. We plan to convert the exis...
Nektar in Medical Technology

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...N CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- nektar Therapeutics (Nasdaq: NKTR ) today reported its ...per share in the second quarter of 2008. nektar made improvements to its operating efficiencies as...09 is approximately $27.4 million of investment in nektar preclinical and clinical development programs. ...

Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)

... CARLOS, Calif., March 2 /PRNewswire-FirstCall/ -- nektar Therapeutics (Nasdaq: NKTR ) announced positive ...rm with small molecules is a major achievement for nektar and sets the stage for the future growth of our pi...009. The results of the Phase 2 study will enable nektar to evaluate the drug in Phase 3 pivotal trials in ...

Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)

...ly- characterized K-Ras mutant patient population, nektar will initiate a prospective study to evaluate the ...and clinical investigators," said Howard W. Robin, nektar President and CEO. "We've seen significant and rep...wt/page/asco . About NKTR-102 (PEG-irinotecan) nektar is developing NKTR-102, a PEGylated form of irinot...

Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)

... Time on June 2, 2008 through a link posted on the nektar website: http://www.nektar.com/wt/page/asco . A r...reet Chicago, IL 60610 About Nektar nektar Therapeutics is a biopharmaceutical company that d...Gylation and pulmonary drug development platforms. nektar PEGylation technology has enabled eight approved p...

Amikacin Inhale Shows Promising Results in Phase II Study

... - Bayer together with nektar Therapeutics present preliminary Phase II data ...swire-FirstCall/ -- Bayer HealthCare together with nektar Therapeutics (Nasdaq: NKTR ), today presented pos... developed by Bayer HealthCare in cooperation with nektar Therapeutics, combining a special liquid formulati...

Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings

...y (ASCO) 2008 Annual Meeting in Chicago, Illinois. nektar will also present its Phase 2 clinical development...ion of NKTR-102. The Phase 1 trial, sponsored by nektar Therapeutics, includes clinical sites at Translati...ktar.com/wt/page/nktr102media . About NKTR-102 nektar is developing NKTR-102, a PEGylated form of irinot...

NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting

...day. Prior Clinical Study Results for NKTR-118 nektar previously presented results from a proof-of-princ... the most common opioid-related side effects.(2) nektar PEGylation Platform nektar PEGylation technology can enhance the properties o...

Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting

...all/ -- Positive preclinical data was presented by nektar Therapeutics (Nasdaq: NKTR ) this week for its le...ctal cancer therapy in combination with cetuximab. nektar had previously announced its intention to expand t...ktar.com/wt/page/nktr102media . About NKTR-102 nektar is developing NKTR-102, a PEGylated form of irinot...

Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings

... SAN FRANCISCO, April 10 /PRNewswire-FirstCall/ -- nektar Therapeutics (Nasdaq: NKTR ) announced today that...l oncology conferences this year. About Nektar nektar Therapeutics is a biopharmaceutical company that d...d pulmonary drug development technology platforms. nektar PEGylation and pulmonary technology, expertise, ma...

Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients

...nd CEO of Nektar. "Fortunately, over the past year nektar has significantly transformed its business, moving...rietary drugs in various stages of development." nektar will cease all spending associated with its inhale...or history of cigarette smoking." About Nektar nektar Therapeutics is a biopharmaceutical company that d...
Nektar in Biological Technology

Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder

SAN CARLOS, Calif., Oct. 21 /PRNewswire-FirstCall/ -- (11:00 PM PT, Oct. 20) -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that Novartis AG has agreed to acquire from Nektar specific pulmonary delivery assets, technology, and intellectual property for $115 million in cash. "This ag...

Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit

SAN CARLOS, Calif., May 22 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that Bharatt Chowrira, Ph.D., J.D. has joined the Company as Chief Operating Officer and Head of the PEGylation Business Unit. His responsibilities include overseeing and managing all aspe...

West Concludes Agreement with Nektar

- Expects to Recover Investments in Dedicated Assets - LIONVILLE, Pa., Feb. 13 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST ) today announced that it has concluded an agreement with Nektar Therapeutics, Inc., relating to the manufacture and assembly of comp...

Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City

... CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- nektar Therapeutics (Nasdaq: NKTR ) is scheduled to pre...Investor Relations, Events Calendar section of the nektar website: http://www.nektar.com . This Webcast...le for replay until August 31, 2009. About nektar ...

Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets

... CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- nektar Therapeutics (Nasdaq: NKTR ) will announce its f...he home page and Investor Relations section of the nektar website: http://www.nektar.com . The web broa...de available on the Investor Relations page at the nektar website as soon as practical after the conclusion ...

World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

...Corporation, Crucell N.V., Flamel Technologies S.A., Elan Corporation Plc, Enzon Pharmaceuticals Inc., Life Technologies Corporation, Nanosphere Inc., nektar Therapeutics, Novavax Inc., Oxonica Plc, Par Pharmaceutical Companies Inc., Starpharma Holdings Limited, and Wyeth Pharmaceuticals Inc., among others....

Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer

...N CARLOS, Calif., June 9 /PRNewswire-FirstCall/ -- nektar Therapeutics (Nasdaq: NKTR ) today announced the...iometrics and Data Management. Dr. Masuoka joined nektar in August 2008 as Vice President of Clinical Devel... and is board certified in Neurology. About nektar ...

Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer

...nd business development for Tercica, Inc., which was acquired by Ipsen in 2008. From February 2003 to January 2006, he was chief financial officer of nektar Therapeutics. From July 2002 until joining Nektar, Mr. Bansal was director of operations analysis at Capital One Financial and, from August 1998 to J...

Nektar Therapeutics Reports First Quarter 2009 Financial Results

...AN CARLOS, Calif., May 6 /PRNewswire-FirstCall/ -- nektar Therapeutics (Nasdaq: NKTR ) today reported its ...44 per share in the first quarter of 2008. nektar made improvements to its operating efficiencies as...linical pipeline and a proven technology platform, nektar is well-positioned to enter into strategic, high-v...

Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program

...pliance and Quality Operations at Chiron Biopharma. In addition, Dr. Scaife held the position of Vice President of Quality and Regulatory Affairs for nektar Therapeutics, Vice President of Global Regulatory Affairs for Elan Pharmaceuticals, and various regulatory and clinical development positions for Nova...
Other Tags
(Date:9/1/2015)... ... September 01, 2015 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... it Red for Lymphoma awareness initiative, the nation’s premier and most high-profile lymphoma ...
(Date:9/1/2015)... ... September 01, 2015 , ... Celebrity hairstylist and Beauty Gives ... “The Beauty Behind the Fashion” on Thursday, Oct. 1, at the La Valencia Hotel. ... spotlight on the collaboration between fashion and professional hair, makeup and nail design. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Philanthropic giving in the U.S. has been stuck ... Money for Good 2015, released today by Camber Collective, goes to the root of ... mobilize up to $22B in new philanthropic giving and shift $25B that’s already being ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... aid colleges and universities across the country in stemming sexual assaults on their ... Climate Collaborative (ARC3), a consortium of sexual assault researchers and student affairs professionals ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... members of the American Society for Dermatologic Surgery, according to a new survey ... ASDS Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Georgia State, Partners Introduce Climate Survey to Aid in Preventing Campus Sexual Assaults 2Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3
(Date:9/1/2015)... Calif. , Sept. 1, 2015  Automation ... travelers during airport passenger screening. This is the ... passenger screening process will become unintrusive. An assortment ... based on voluntary background investigations will transform the ... Frost & Sullivan, Global Airport Passenger Screening ...
(Date:8/31/2015)... BURNABY, Canada , August 31, 2015 ... use of biometrics technology in government digitization projects to drive ... According to a recently published TechSci Research report, " India ... India is projected to grow at ... in the market is anticipated on account of extensive use ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends ... The Saudi Arabia Biomedical Sensors market is ... of 3.64% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
Breaking Biology News(10 mins):The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2
Other Contents